Immediate postoperative measurement of thyroid-stimulating hormone as an early predictor of remission in thyroid-stimulating hormone?secreting pituitary adenomas

被引:6
|
作者
Kim, Soo Heon [1 ]
Ku, Cheol Ryong [2 ,3 ,4 ]
Na, Minkyun [1 ]
Yoo, Jihwan [1 ]
Kim, Woohyun [1 ]
Jung, In-Ho [1 ]
Kim, Kyung Won [2 ]
Moon, Ju Hyung [1 ,3 ,4 ]
Kim, Daham [2 ,3 ,4 ]
Lee, Eun Jig [2 ,3 ,4 ]
Kim, Sun Ho [1 ,5 ]
Kim, Eui Hyun [1 ,3 ,4 ]
机构
[1] Yonsei Univ, Dept Neurosurg, Coll Med, Seoul, South Korea
[2] Yonsei Univ, Dept Internal Med, Div Endocrinol & Metab, Coll Med, Seoul, South Korea
[3] Severance Hosp, Pituitary Tumor Ctr, Seoul, South Korea
[4] Yonsei Univ, Yonsei Endocrine Res Inst, Coll Med, Seoul, South Korea
[5] Ewha Womans Univ, Dept Neurosurg, Coll Med, Seoul, South Korea
关键词
hyperthyroidism; pituitary adenoma; remission; thyroid-stimulating hormone; transsphenoidal surgery; pituitary surgery;
D O I
10.3171/2020.1.JNS192787
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE Thyroid-stimulating hormone (TSH)-secreting pituitary adenoma (TSHoma) is a rare type of pituitary adenoma; thus, little is known about TSHomas. The purpose of this study was to analyze clinical characteristics and therapeutic outcomes of TSHomas based on a single-center experience. The authors also searched for reliable preoperative and early postoperative factors that could predict long-term endocrinological remission. METHODS The clinical, radiological, and pathological characteristics and surgical and endocrinological outcomes of 31 consecutive cases of TSHomas that were surgically treated between 2005 and 2017 were reviewed retrospectively. Preoperative factors were evaluated for their ability to predict long-term remission by comparing remission and non remission groups. TSH and free thyroxine levels were measured at 2, 6, 12, 18, and 24 hours after surgery to determine whether they could predict long-term remission. RESULTS Gross-total removal of tumor was achieved in 28 patients (90.3%), and 26 patients (83.9%) achieved endocrinological remission by surgery alone based on long-term endocrinological follow-up (median 50 months, range 32-81 months). The majority of the tumors were solid (21/31, 67.7%), and en bloc resection was possible in 16 patients (51.6%). Larger tumor size and tumor invasion into cavernous sinus and sphenoid sinus were strong predictors of lower rates of endocrinological remission. Immediate postoperative TSH level at 12 hours after surgery was the strongest predictor, with a 0.62 mu IU/mL cutoff. Postoperative complications included CSF rhinorrhea in one patient and epistaxis in another patient, who underwent additional surgical treatment for the complications. CONCLUSIONS Tumor size and extent are major prognostic factors for both extent of resection and endocrinological remission. The consistency of TSHomas was more likely to be solid, which makes extracapsular dissection more feasible. Long-term remission of TSHomas could be predicted even during the early postoperative period. https://thejns.org/doi/abs/10.3171/2020.1.JNS192787
引用
收藏
页码:794 / 800
页数:7
相关论文
共 50 条
  • [31] Photoperiodic regulation of pituitary thyroid-stimulating hormone and brain deiodinase in Atlantic salmon
    Irachi, Shotaro
    Hall, Daniel J.
    Fleming, Mitchell S.
    Maugars, Gersende
    Bjornsson, Bjorn Thrandur
    Dufour, Sylvie
    Uchida, Katsuhisa
    McCormick, Stephen D.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2021, 519
  • [32] The Effect of Thyroid-Stimulating Hormone on Tumor Size in Differentiated Thyroid Carcinoma
    I. A. Ozemir
    B. Gurbuz
    B. Bayraktar
    S. Aslan
    A. Başkent
    H. Yalman
    R. Yigitbasi
    O. Alimoglu
    Indian Journal of Surgery, 2015, 77 : 967 - 970
  • [33] Thyroid-Stimulating Antibody/Thyroid-Stimulating Hormone Receptor Antibody Ratio as a Sensitive Screening Test for Active Graves' Orbitopathy
    Nakano, Masayoshi
    Konishi, Hiroe
    Koshiba, Masahiro
    ENDOCRINE PRACTICE, 2022, 28 (10) : 1050 - 1054
  • [34] SECRETION OF GROWTH-HORMONE AND THYROID-STIMULATING HORMONE IN PATIENTS WITH DEMENTIA
    GOMEZ, JM
    AGUILAR, M
    NAVARRO, MA
    ORTOLA, J
    SOLER, J
    CLINICAL INVESTIGATOR, 1994, 72 (07): : 489 - 493
  • [35] Similar Clinical Performance of a Novel Chimeric Thyroid-Stimulating Hormone Receptor Bioassay and an Automated Thyroid-Stimulating Hormone Receptor Binding Assay in Graves' Disease
    Kamijo, Keiichi
    Murayama, Hiroshi
    Uzu, Takahiro
    Togashi, Kazuyoshi
    Olivo, Paul D.
    Kahaly, George J.
    THYROID, 2011, 21 (12) : 1295 - 1299
  • [36] Active and Silent Thyroid-Stimulating Hormone-Expressing Pituitary Adenomas: Presenting Symptoms, Treatment, Outcomes, and Recurrence
    Kirkman, Matthew A.
    Jaunmuktane, Zane
    Brandner, Sebastian
    Khan, Akbar A.
    Powell, Michael
    Baldeweg, Stephanie E.
    WORLD NEUROSURGERY, 2014, 82 (06) : 1224 - 1231
  • [37] The association between thyroid-stimulating hormone and thyroid nodules, goiter and thyroid antibody positivity
    Li, Shaohan
    Guo, Wenxing
    Meng, Qi
    Zhu, Mei
    Wei, Hongyan
    Ji, Fengying
    Tan, Long
    Zhang, Wanqi
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [38] Bone Turnover in Relation to Thyroid-Stimulating Hormone in Hypothyroid Patients on Thyroid Hormone Substitution Therapy
    Bjerkreim, Betty Ann
    Hammerstad, Sara S.
    Eriksen, Erik Fink
    JOURNAL OF THYROID RESEARCH, 2022, 2022
  • [39] Thyroid function in early normal pregnancy: Transient suppression of thyroid-stimulating hormone and stimulation of triiodothyronine
    Kol, S
    Karnieli, E
    Kraiem, Z
    ItskovitzEldor, J
    Lightman, A
    IshShalom, S
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1996, 42 (04) : 227 - 229
  • [40] Cord blood thyroid-stimulating hormone level in twin pregnancy
    Chan, LYS
    Chiu, PY
    Lau, TK
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2003, 82 (01) : 28 - 31